Sun Pharma launches new campaign with actor Akshay Kumar
The 360 degree campaign for Sun Pharma's consumer healthcare brand, Revital H, will air in eight key languages across TV, digital platforms and print pan India.18-10-2022
18-10-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201518-10-2022
Hot Stocks | Here's why you should bet on Sun Pharma, Mphasis for the short term
Technically speaking, Sun Pharma prices are continuing with higher highs and higher lows cycle and the way momentum oscillators are poised, we will not be surprised to see this stock entering the 4-digit territory soon.17-10-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201513-10-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 12, 2022 for Raksha Sudhir Valia12-10-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sun Pharma to announce second quarter results on November 01, 202211-10-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Board Meeting Intimation for Approval Of Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2022
SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/11/2022 ,inter alia, to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 202210-10-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Submission of Certificate under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 202210-10-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201510-10-2022
Sun Pharma's Shanghvito participate in Suzlon rights issue
Holds around 11 % stake in the wind-turbine maker07-10-2022